A recent phase III trial of the MET kinase inhibitor cabozantinib in men with castration-
resistant prostate cancer (CRPC) failed to meet its primary survival end point; however, most …

Despite recent improvements in patient outcomes using newer androgen receptor (AR)
pathway inhibitors, treatment resistance in castrate resistant prostate cancer (CRPC) …

Although androgen ablation therapy is the foundation of current prostate cancer treatment,
most patients ultimately develop castration-resistant disease. One proposed mechanism to …

Next-generation antiandrogen therapies, such as enzalutamide and abiraterone, have had a
profound impact on the management of metastatic castration-resistant prostate cancer …

BACKGROUND Two androgen receptor (AR)‐targeted therapies, enzalutamide and
abiraterone acetate plus prednisone (abiraterone), have been approved for the treatment of …

Effective management of bone metastases in men with castration-resistant prostate cancer
(CRPC) remains an important unmet medical need. MET and vascular endothelial growth …

Background Non-metastatic castration resistant prostate cancer (M0CRPC) is a
heterogenous disease state affecting an estimated 100,000 men in the United States …

Background Prostate cancer that recurs after initial treatment inevitably progresses to
castration‐resistant prostate cancer (CRPC), the lethal stage of the disease. Despite …

Continued reliance on the androgen receptor (AR) is now understood as a core mechanism
in castration-resistant prostate cancer (CRPC), the most advanced form of this disease …

The overall goal of this study was to elucidate the role of FGFR1 induction in acquired
resistance to MET and VEGFR2 inhibition by cabozantinib in prostate cancer (PCa) and …